Extending venom therapy intervals reduces risk without sacrificing safety
Patients with systemic mastocytosis can safely extend venom immunotherapy (VIT) maintenance intervals to 12 weeks after five years.
News
-
-
Patients with SM and multiple cancers have reduced overall survival
Multiple cancers is a risk factor for a poorer prognosis in SM.
-
Study finds rising incidence and cancer risk in US systemic mastocytosis cases
New study reveals rising U.S. rates of systemic mastocytosis and increased risk of secondary cancers, especially in older adults.
-
Sarilumab does not improve quality of life in patients with indolent SM
A clinical trial of 16 patients with indolent SM found that sarilumab does not significantly improve quality of life.
-
Case report: SM uncovered in leukemia patient after missed diagnosis
A man with acute myeloid leukemia was also diagnosed with systemic mastocytosis after late bone marrow tests.
-
Researchers highlight role of tryptase genotyping in diagnosing mastocytosis
Tryptase genotyping helps determine whether a high tryptase level reflects disease or genetics in systemic mastocytosis (SM).
-
Anemia as initial presentation of SM: Case report
A recent case study highlights how anemia and low platelet counts can be the initial presentation of systemic mastocytosis (SM).
-
Study reveals risk of skin cancer rises in patients with mastocytosis
Patients with systemic mastocytosis (SM) face significantly increased risks of melanoma and other skin cancers.
-
Case report examines SM as a cause of chronic diarrhea
A recently published case report highlighted systemic mastocytosis (SM) as a possible cause of chronic diarrhea.
-
Antisense therapy targeting KIT mutations shows potential as SM treatment
HT-KIT cut KIT protein levels by more than 80% and halted tumor growth in systemic mastocytosis (SM) models.
Learn more about SM
Sign up for the latest news, perspectives, and information about SM.
